WO2006012403A1 - Procédés de traitement : signalisation des cellules et libération de glutamate - Google Patents

Procédés de traitement : signalisation des cellules et libération de glutamate Download PDF

Info

Publication number
WO2006012403A1
WO2006012403A1 PCT/US2005/025853 US2005025853W WO2006012403A1 WO 2006012403 A1 WO2006012403 A1 WO 2006012403A1 US 2005025853 W US2005025853 W US 2005025853W WO 2006012403 A1 WO2006012403 A1 WO 2006012403A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
endocannabinoid
syndrome
compound
agonist
Prior art date
Application number
PCT/US2005/025853
Other languages
English (en)
Inventor
Mark F. Bear
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Publication of WO2006012403A1 publication Critical patent/WO2006012403A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Definitions

  • cell signaling includes the release of an intracellular signaling molecule, a neurotransmitter, such as glutamate, from a presynaptic neuron into the synaptic cleft. Once released, a neurotransmitter can mediate cellular signaling by affecting postsynaptic neurons.
  • a neurotransmitter such as glutamate
  • Certain conditions e.g., mental retardation, Down's syndrome, autism and fragile X syndrome
  • subjects such as humans, have been associated with or believed to be a consequence of inappropriate neuronal cell signaling.
  • treatments for certain conditions such as mental retardation, fragile X syndrome, Down's syndrome and autism, may not result in appropriate neuronal cell signaling.
  • the present invention is directed to methods of treating subjects, including human subjects having mental retardation, fragile X syndrome, Down's syndrome and autism.
  • the invention is a method of treating a subject, comprising the step of administering at least one compound that down regulates endocannabinoid signaling to a subject having at least one condition selected from the group consisting of mental retardation, Down's syndrome, fragile X syndrome and autism.
  • the invention is a method of treating a subject, comprising the step of administering at least one agonist selected from the group consisting of a Group II niGluR agonist and a Group III mGluR agonist.
  • the invention is a method of treating a human, comprising the step of administering a compound that down regulates presynaptic glutamate release to a subject.
  • the invention described herein is a method for treating subjects, including humans having mental retardation, fragile X syndrome, Down's syndrome and autism. Appropriate neuronal signaling can be restored to thereby halt, reverse or diminish the progression of inappropriate neuronal signaling to increase the quality of life for the subject.
  • Figure 1 depicts neuronal signaling between presynaptic and postsynaptic neurons in the endocannabinoid signaling pathway.
  • Figure 2 depicts neuronal signaling of presynaptic neurons expressing Group
  • the present invention is directed to methods of treating subjects, including humans with mental retardation, fragile X syndrome, Down's syndrome and autism.
  • subjects including humans with mental retardation, fragile X syndrome, Down's syndrome and autism.
  • the subject having fragile X syndrome can also have autism.
  • Group I mGluR metalabotropic glutamate receptor
  • LTD long term depression
  • FMRP fragile X mental retardation protein
  • mGluRs are a heterogeneous family of glutamate G-protein coupled receptors. mGluRs are classified into three groups. Group I receptors (mGluRl and mGluRS) can be coupled to stimulation of phospholipase C resulting in phosphoinositide hydrolysis and elevation of intracellular calcium levels, modulation of ion channels (e.g.,potassium channels, calcium channels, non-selective cation channels) and N-methyl-D-aspartate (NMDA) receptors.
  • ion channels e.g.,potassium channels, calcium channels, non-selective cation channels
  • NMDA N-methyl-D-aspartate
  • mGluR5 can be present on a postsynaptic neuron.
  • niGlurl can be present on a presynaptic neuron and/or a postsynaptic neuron.
  • Group II receptors niGluR2 and niGluR3
  • Group III receptors mGluRs 4, 6, 7, and 8
  • Group II mGluRs and Group III mGluRs are negatively coupled to adenylyl cyclase, generally present on presynaptic neurons, but can be present on postsynaptic neurons and function as presynaptic autoreceptors to reduce glutamate release from presynaptic neurons.
  • the invention is a method of treating a subject, comprising the step of administering at least one compound that down regulates endocannabinoid signaling to a subject having at least one condition selected from the group consisting of mental retardation, Down's syndrome, fragile X syndrome and autism.
  • Down regulates refers to any decrease or any inhibition in a cellular process or a cellular event or intermediate in a cellular event associated with the biological or cellular process (e.g., endocannabinoid signaling, protein synthesis, glutamate release).
  • endocannabinoid signaling are employed in the methods of the invention.
  • compounds that down regulate presynaptic glutamate release are employed in the methods of the invention.
  • Compounds that down regulate endocannabinoid signaling can down regulate presynaptic glutamate release.
  • Down regulation of endocannabinoid signaling can be, for example, the prevention or any decrease in binding of a signal external to a cell (a first messenger), such as a ligand (e.g., glutamate), to a endocannabinoid receptor (e.g., a presynaptic CBl receptor).
  • Down regulation can be disruption of a cellular process following binding of an external signal (e.g., ligand) to an endocannabinoid receptor, such as the prevention of activation of adenylyl cyclase, phospholipase C (PLC) or phospholipase D (PLD).
  • an external signal e.g., ligand
  • PLC phospholipase C
  • PLD phospholipase D
  • Down regulation can also be disruption of a cellular process following binding of an external signal to an endocannabinoid receptor, such as the prevention of activation of a G-protein (Gs, Gq), a decrease in a G-protein (Gs, Gq) activation, prevention of activation of second messengers activated by endocannabinoid receptors (e.g., cAMP, IP 3 , diacylglycerol (DAG), PLC, PLD) or a decrease in the activity of an intracellular effector, such as a cAMP -dependent protein kinase, protein kinase C (PKC) or calcium release.
  • Gs, Gq G-protein
  • Gs, Gq G-protein activation
  • second messengers activated by endocannabinoid receptors e.g., cAMP, IP 3 , diacylglycerol (DAG), PLC, PLD
  • a decrease in the activity of an intracellular effector such as
  • Figure 1 depicts down regulation of endocannabinoid signaling by, for example, the use of inhibitors (also referred to herein as "antagonists") of presynaptic CBl receptors and thereby treatment of mental retardation, fragile X syndrome, Down's syndrome and autism in a human.
  • inhibitors also referred to herein as "antagonists”
  • a ligand e.g., endocannabinoid
  • an endocannabinoid receptor e.g., CBl receptor
  • Interfere as used herein when referring to binding of a ligand to a receptor, means any effect on ligand-receptor binding that occurs in the presence of the compound that prevents the ligand from activating the receptor or mediating cell signaling.
  • Compounds used in the methods of the invention that down regulate endocannabinoid signaling can alter processes in cell signaling pathways, such as cAMP-dependent protein kinase.
  • "Alter,” as used herein in reference to cell signaling pathways means any difference in the cell signaling pathway, molecule or intermediate in the cell signaling pathway that occurs in the presence of the compound that is not observed in the absence of the compound.
  • An alteration can be, for example, a structural change in a protein kinase that inhibits activity of a protein kinase that was activated by ligand binding to a cell surface receptor, such as an endocannabinoid receptor or a Group II mGluR or a Group III mGluR.
  • Compounds that down regulate endocannabinoid signaling can be antagonists of endocannabinoid receptors, such as a CBl endocannabinoid receptor antagonist.
  • the CBl endocannabinoid receptor antagonists can be natural or synthetic antagonists of CBl receptors. Suitable CBl endocannabinoid antagonists are, for example,
  • An antagonist of an endocannabinoid receptor is a substance that diminishes or abolishes the effect of a ligand (an endocannabinoid or agonist of an endocannabinoid) that activates an endocannabinoid receptor.
  • the endocannabinoid antagonist may act at the level of ligand-receptor interaction, such as by competitively or non-competitively (e.g., allosterically) inhibiting endocannabinoid binding.
  • the endocannabinoid antagonist can be, for example, a chemical antagonist or a pharmacokinetic antagonist.
  • the endocannabinoid antagonist may act downstream of the receptor, such as by inhibiting receptor interaction with a G- protein or subsequent cell signaling events associated with G-protein activation, such as activation of PLC, an increase in intracellular calcium, the production of or levels of cAMP or adenyl cyclase and stimulation or modulation of ion channels (e.g., potassium channels, calcium channels).
  • ion channels e.g., potassium channels, calcium channels.
  • a pharmacokinetic antagonist can decrease the concentration of a ligand (e.g., endocannabinoid) at a site of action, for example, by increasing the rate of metabolic degradation of the active ligand.
  • Antagonism by a compound that reduces endocannabinoid signaling can involve reversible competitive antagonism or irreversible, or non-equilibrium, competitive antagonism.
  • Reversible competitive antagonism occurs when the rate of dissociation of the antagonist from the receptor is sufficiently high that, on addition of the ligand, the antagonist molecules binding the receptors are effectively replaced by the ligand.
  • Irreversible or non-equilibrium competitive antagonism occurs when the antagonist dissociates very slowly or not at all from the receptor, with the result that no change in the antagonist occupancy takes place when the ligand is applied.
  • a competitive antagonist refers to a compound that binds to the endocannabinoid receptor or to the endocannabinoid signaling ligand in a manner that sterically interferes with the interaction of the endocannabinoid with the receptor.
  • the endocannabinoid antagonist does not compete directly with endocannabinoid binding at the receptor, yet blocks a point in the signal transduction pathway subsequent to receptor activation by the ligand.
  • Down regulation of endocannabinoid signaling can also be through activation of Group II and/or Group III mGluRs by, for example, agonists of presynaptic Group II and Group III mGluRs ( Figure 2).
  • An "agonist,” as used herein, is a compound that activates cell signaling.
  • the agonist also referred to herein as an activator
  • the agonist can be a natural or synthetic ligand for a Group II mGluR or Group III mGluR.
  • Activation of cell signaling can be, for example, an increase in the affinity or binding of a signal external to a cell (a second messenger), such as a ligand (e.g., glutamate) for a Group II and/or a Group III mGluR (e.g., a presynaptic Group II and/or Group III mGluR).
  • a second messenger such as a ligand (e.g., glutamate) for a Group II and/or a Group III mGluR (e.g., a presynaptic Group II and/or Group III mGluR).
  • Activation of cell signaling can be any increase or augmentation of a cellular process following binding of an external signal (e.g., a ligand) to a Group II and/or Group III mGluR, such as activation of adenyl cyclase, PLC or PLD.
  • Activation of cell signaling can also be any increase in a cellular process following binding of an external ligand to a Group II and/or Group III mGluR, such as activation of a G-protein, activation of second messengers (e.g., cAMP, IP 3 , DAG, PLC, PLD) or any increase in the activity or amount of an intracellular effector, such as a cAMP-dependent protein kinase, PKC or calcium release.
  • Figure 2 depicts activation of Group II mGluR and/or Group III mGluR by, for example, a Group II niGluR agonist and/or a Group III mGluR agonists and thereby treatment of a subject.
  • Group I and Group II mGluR agonists for use in the invention include LY354740, L-AP4 (Capogna, M. Eur. J. Neurosci. 19: 2847-2858 (2004), the teachings of which are hereby incorporated by reference in their entirety)
  • the invention is a method of treating a subject, comprising the step of administering at least one agonist selected from the group consisting of a Group II mGluR agonist and a Group III mGluR agonist.
  • the Group ⁇ mGluR agonist and Group III mGluR agonist can be an agonist of a presynaptic neuron and/or a postsynaptic neuron of a Group II mGluR and/or a Gropu III mGluR.
  • the invention is a method of treating a human comprising the step of administering a compound that down regulates presynaptic glutamate release to the human.
  • the compound that down regulates presynaptic glutamate release can be an endocannabinoid antagonist (e.g., a presynaptic CBl receptor agonist), a Group II mGluR antagonist and/or a Group III mGluR antagonist.
  • a subject treated by the methods described herein can be any mammal, such as a rodent (e.g., rat, mouse, guinea pig) or a primate (e.g., monkey, baboon, human).
  • the methods of the invention can be employed to treat humans with mental retardation.
  • Mental retardation is characterized by a significantly below-average score on a test of mental ability or intelligence and by limitations in the ability to function in areas of daily life, such as communication, self-care, and getting along in social situations and school activities.
  • Mental retardation can be caused, for example, by injury, disease or a brain abnormality that can occur before a child is born, during childhood or during adulthood.
  • Some of the most common known causes of mental retardation are genetic causes, as in Down's syndrome and fragile X syndrome. Other causes that take place before a child is born include genetic conditions, fetal alcohol syndrome, infections or birth defects that affect the brain.
  • the methods of the invention can also be employed to treat fragile X syndrome, a genetic form of mental retardation. Fragile X syndrome is diagnosed by a genetic test that determines the number of CGG repeats in the 5' untranslated region of the fragile X mental retardation (FMRl) gene that results in transcriptional silencing of the fragile X mental retardation protein
  • the methods of the invention can be employed to treat Down's Syndrome, another genetic cause of mental retardation. Humans with Down's syndrome have a tri-semi-chromosome 21 failure of chromosomes to separate.
  • the methods of the invention can be employed to treat autism. Characteristics of autism include deficits in social skills, and verbal and non-verbal communication and can be accompanied by restricted, repetitive or stereotypic behavior.
  • a human with autism can also have fragile X syndrome.
  • One of skill in the art would be capable of diagnosing a subject with mental retardation, fragile X syndrome, Down's syndrome and autism who would benefit from the methods of the invention.
  • an “effective amount,” also referred to herein as a "therapeutically effective amount,” when referring to the amount of a compound or composition (e.g., pharmaceutical composition containing a compound) for use in the methods of the invention, is defined as that amount, or dose, of a compound or composition that, when administered to a subject, is sufficient for therapeutic efficacy (e.g., an amount sufficient decrease glutamate release, to exhibit a clinical improvement in a behavior or mental cognitive test score).
  • the methods of the present invention can be accomplished, for example, by the administration of a compound by enteral or parenteral means. Specifically, the route of administration is by oral ingestion (e.g., tablet, capsule form).
  • routes of administration as also encompassed by the present invention including intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous routes and nasal administration.
  • Suppositories or transdermal patches can also be employed.
  • Group II niGluR e.g., a ligand or agonist of Group II mGluR
  • activate Group III niGluR e.g., a ligand or agonist of Group III mGluR
  • presynaptic glutamate can be administered to the subject.
  • the subject can be treated with a compound that down regulates endocannabinoid signaling by preventing binding of endocannabinoid to a presynaptic CB 1 receptor or a compound that disrupts intracellular signaling following binding of an endocannabinoid to an endocannabinoid receptor.
  • a compound that decreases presynaptic glutamate can increase binding of a ligand or an agonist of a Group ⁇ mGluR or a ligand or an agonist of a Group III mGluR to a presynaptic neuron.
  • Compounds that down regulate endocannabinoid signaling, activate Group II mGluR, activate Group III mGluR or decrease presynaptic glutamate can be co-administered. Coadminstration can include simultaneous or sequential administration of such compounds. Compounds that down regulate endocannabinoid signaling, activate Group II mGluR, activate Group III niGluR or decrease presynaptic glutamate can be administered alone or can be coadministered to the subject with another treatment regimen.
  • Compounds that down regulate endocannabinoid signaling, activate Group II mGluR, activate Group III mGluR or decrease presynaptic glutamate can be administered alone or as admixtures with conventional excipients, for example, pharmaceutically, or physiologically, acceptable organic, or inorganic carrier substances suitable for enteral or parenteral application which do not deleteriously react with the compounds.
  • suitable pharmaceutically acceptable carriers include water, salt solutions (such as Ringer's solution), alcohols, oils, gelatins and carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, and polyvinyl pyrolidine.
  • Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like which do not deleteriously react with the compound used in the methods of the invention.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like which do not deleteriously react with the compound used in the methods of the invention.
  • the preparations can also be combined, when desired, with other active substances to reduce metabolic degradation.
  • the compound for use in the methods of the invention can be administered in a single or in more than one dose over a period of time to confer the desired effect (e.g., alleviate urges and repetitive actions).
  • the compounds can be administered in a dose of between about 0.5 mg/kg to about 5 mg/kg body weight; or between about 1 mg/kg to about 10 mg/kg body weight.
  • the compounds can be administered in doses of about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 500 mg, about 700 mg, or about 900 mg.
  • the compounds can be administered once a day or multiple times per day.
  • admixtures for a compound that down regulates endocannabinoid, activate Group II mGluR, activate Group III niGluR or decrease presynaptic glutamate are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories.
  • carriers for parenteral administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block polymers, and the like. Ampules are convenient unit dosages.
  • the compound used in the methods of the invention can also be incorporated into liposomes or administered by transdermal pumps or patches.
  • Pharmaceutical admixtures suitable for use in the present invention are well-known to those of skill in the art and are described, for example, in Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, PA) and WO 96/05309 the teachings of which are hereby incorporated by reference.
  • the dosage and frequency (single or multiple doses) administered to a subject can vary depending upon a variety of factors, including, for example, the condition being treated, duration of the condition being treated, the duration of OCD and obsessions and compulsions associated with OCD, age, sex, health, body weight and body mass index of the subject; kind of concurrent treatment, or other health-related problems.
  • Other therapeutic regimens or agents can be used in conjunction with the methods of the present invention. Adjustment and manipulation of established dosages (e.g., frequency and duration) are well within the ability of those skilled in the art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Dans un mode de réalisation, les sujets souffrant d'un retard mental, de la trisomie 21, du syndrome du X fragile et de l'autisme sont traités avec au moins un composé qui freine la signalisation par les endocannabinoïdes. Dans un autre mode de réalisation, les sujets sont traités avec au moins un agoniste choisi dans le groupe constitué d'un agoniste de mGluR du groupe II et d'un agoniste de mGluR du groupe III. Dans encore un autre mode de réalisation, un humain est traité avec un composé qui freine la libération de glutamate présynaptique.
PCT/US2005/025853 2004-07-20 2005-07-20 Procédés de traitement : signalisation des cellules et libération de glutamate WO2006012403A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58967104P 2004-07-20 2004-07-20
US60/589,671 2004-07-20
US67851805P 2005-05-06 2005-05-06
US60/678,518 2005-05-06

Publications (1)

Publication Number Publication Date
WO2006012403A1 true WO2006012403A1 (fr) 2006-02-02

Family

ID=35134168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025853 WO2006012403A1 (fr) 2004-07-20 2005-07-20 Procédés de traitement : signalisation des cellules et libération de glutamate

Country Status (1)

Country Link
WO (1) WO2006012403A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121919A2 (fr) * 2005-05-05 2006-11-16 Massachusetts Institute Of Technology Procedes de traitement de trouble obsessionnel compulsif
WO2007029063A2 (fr) * 2005-07-29 2007-03-15 Ecole Polytechnique Federale De Lausanne (Epfl) Procedes permettant de traiter et/ou de prevenir les troubles pervasifs du developpement chez un sujet
WO2008066750A1 (fr) * 2006-11-22 2008-06-05 Seaside Therapeutics, Llc Procédés de traitement du retard mental, du syndrome de down, du syndrome de l'x fragile et de l'autisme
WO2014064028A1 (fr) * 2012-10-23 2014-05-01 F. Hoffmann-La Roche Ag Antagonistes de mglu2/3 pour le traitement de troubles autistiques
EP2976074B1 (fr) * 2013-03-19 2020-01-01 Universitat Pompeu-Fabra Antagonistes du récepteur cannabinoïde cb1 destinés à être utilisés dans le traitement de maladies associées à des anomalies dendritiques neuronales

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001980A1 (fr) * 1999-07-06 2001-01-11 The Regents Of The University Of California Procedes d'amelioration de troubles neuropsychiatriques par inhibition du transport inactivant de substances cannabinoides endogenes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001980A1 (fr) * 1999-07-06 2001-01-11 The Regents Of The University Of California Procedes d'amelioration de troubles neuropsychiatriques par inhibition du transport inactivant de substances cannabinoides endogenes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEAR M F ET AL: "The mGluR theory of fragile X mental retardation", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 27, no. 7, July 2004 (2004-07-01), pages 370 - 377, XP004516797, ISSN: 0166-2236 *
DOHERTY ET AL: "Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS,, NL, vol. 3, no. 1, February 2003 (2003-02-01), pages 46 - 53, XP005040604, ISSN: 1471-4892 *
MOGHADDAM B: "Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia", PSYCHOPHARMACOLOGY 2004 GERMANY, vol. 174, no. 1, 2004, pages 39 - 44, XP002351790, ISSN: 0033-3158 *
SCHOEPP D D ET AL: "LY354740: A SYSTEMICALLY ACTIVE MGLU2/MGLU3 RECEPTOR AGONIST", CNS DRUG REVIEWS, BRANFORD, CT, US, vol. 5, no. 1, 1999, pages 1 - 12, XP000881011, ISSN: 1080-563X *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121919A2 (fr) * 2005-05-05 2006-11-16 Massachusetts Institute Of Technology Procedes de traitement de trouble obsessionnel compulsif
WO2006121919A3 (fr) * 2005-05-05 2007-08-02 Massachusetts Inst Technology Procedes de traitement de trouble obsessionnel compulsif
WO2007029063A2 (fr) * 2005-07-29 2007-03-15 Ecole Polytechnique Federale De Lausanne (Epfl) Procedes permettant de traiter et/ou de prevenir les troubles pervasifs du developpement chez un sujet
WO2007029063A3 (fr) * 2005-07-29 2007-07-12 Ecole Polytech Procedes permettant de traiter et/ou de prevenir les troubles pervasifs du developpement chez un sujet
US8273715B2 (en) 2006-11-22 2012-09-25 Seaside Therapeutics, Inc. Methods of treating fragile X syndrome
US8143311B2 (en) 2006-11-22 2012-03-27 Seaside Therapeutics, Inc. Methods of treating fragile X syndrome and autism
WO2008066750A1 (fr) * 2006-11-22 2008-06-05 Seaside Therapeutics, Llc Procédés de traitement du retard mental, du syndrome de down, du syndrome de l'x fragile et de l'autisme
EP2567696A1 (fr) * 2006-11-22 2013-03-13 Seaside Therapeutics, Inc. Procédés de traitement du retard mental, du syndrome de Down, du syndrome de l'X fragile et de l'autisme
EP2578216A1 (fr) * 2006-11-22 2013-04-10 Seaside Therapeutics, Inc. Procédés de traitement du syndrome de l'X fragile
US9044443B2 (en) 2006-11-22 2015-06-02 Clinical Research Associates, Llc Methods of treating autism
WO2014064028A1 (fr) * 2012-10-23 2014-05-01 F. Hoffmann-La Roche Ag Antagonistes de mglu2/3 pour le traitement de troubles autistiques
CN104736140A (zh) * 2012-10-23 2015-06-24 霍夫曼-拉罗奇有限公司 用于治疗自闭症的mGlu2/3拮抗剂
EP2976074B1 (fr) * 2013-03-19 2020-01-01 Universitat Pompeu-Fabra Antagonistes du récepteur cannabinoïde cb1 destinés à être utilisés dans le traitement de maladies associées à des anomalies dendritiques neuronales

Similar Documents

Publication Publication Date Title
Malmberg et al. Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on the formalin test in the rat.
DE69534341T2 (de) Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und spasmen an einer wunde
Lapin Phenibut (β‐phenyl‐GABA): A tranquilizer and nootropic drug
Calcutt et al. Spinal pharmacology of tactile allodynia in diabetic rats
Krystal et al. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability
Pertovaara et al. Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective α2‐adrenoceptor antagonist
Paul et al. Efficacy of intra-articular dexmedetomidine for postoperative analgesia in arthroscopic knee surgery
RU2244558C2 (ru) Анестетическая композиция, включающая антагонист nmda и альфа-2 адренергический агонист
Becker et al. Neurochemical mechanisms of alcohol withdrawal
Dunbar et al. Concurrent spinal infusion of MK801 blocks spinal tolerance and dependence induced by chronic intrathecal morphine in the rat
JPH10510540A (ja) 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
CZ20021904A3 (cs) Pyrrolidinacetamidový derivát samotný nebo v kombinaci pro léčení poruch CNS
Takano et al. Antihyperalgesic effects of intrathecally administered magnesium sulfate in rats
Inturrisi Preclinical evidence for a role of glutamatergic systems in opioid tolerance and dependence
US20140213621A1 (en) Method for treatment of chronic neuropathic pain
WO2006012403A1 (fr) Procédés de traitement : signalisation des cellules et libération de glutamate
AU2003287006A1 (en) Preventing desensitization of receptors
Pinardi et al. Interaction between the antinociceptive effect of ketoprofen and adrenergic modulatory systems
US20090035219A1 (en) CB1 receptor antagonists and uses thereof
Stepanović-Petrović et al. Levetiracetam synergizes with gabapentin, pregabalin, duloxetine and selected antioxidants in a mouse diabetic painful neuropathy model
Kekesi et al. The antinociceptive potencies and interactions of endogenous ligands during continuous intrathecal administration: adenosine, agmatine, and endomorphin-1
Ibuki et al. Spinal amino acid release and repeated withdrawal in spinal morphine tolerant rats
De Kock et al. α2-Adrenoceptor agonists and stress-induced analgesia in rats: Influence of stressors and methods of analysis
EP1267849B1 (fr) Substances diminuant la reapparition de l'usage de drogues
Blake THE GENERAL VERSUS REGIONAL ANAESTHESIA DEBATE: TIME TO RE‐EXAMINE THE GOALS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase